Polycythemia Vera: Evidence-Based Clinical Summary

On this page

Quick Reference

RxDrug of choiceFirst-line: hydroxyurea 500-1000 mg PO daily for high-risk patients. Alternative 1st-line: ropeginterferon alfa-2b 250-500 µg SC every 2 weeks. For HU-resistant/intolerant: ruxolitinib 10 mg PO BID.

AltAlternativesPeginterferon alfa-2a 90-180 µg SC weekly; rusfertide (hepcidin mimetic, investigational) 40-80 mg SC weekly; buserelin not used in PV.

⊘AvoidAvoid non-dihydropyridine CCBs (diltiazem, verapamil), no direct role in PV; avoid aspirin if platelet count >1000 × 10⁹/L; restrict hydroxyurea in pregnancy; avoid ruxolitinib in pregnancy (insufficient safety data).

DxTest of choiceJAK2 V617F mutation testing on peripheral blood (first-line molecular test); if negative, JAK2 exon 12 sequencing. Bone marrow biopsy with trephine core for histologic confirmation.

ScKey scoreIWG-MRT risk stratification: low-risk (age <60 + no prior thrombosis) vs high-risk (age ≥60 or prior thrombosis). Also QRISK3 score (>7.5% predicts 2.1x HR for thrombosis).

→When to referNew diagnosis for risk stratification and cytoreduction decision; suspected disease transformation (cytopenias, splenomegaly, blasts); pregnancy; intolerance/resistance to first-line therapy; consideration for clinical trial (rusfertide, novel JAK inhibitors).

All PV patients need phlebotomy to Hct <45% and low-dose aspirin. High-risk patients (age >60 or prior thrombosis) need cytoreduction, start hydroxyurea; use interferon in younger/pregnant patients; ruxolitinib for HU failures. Untreated thrombosis risk is 5%/year; with optimal management, median survival is 17 years.

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm driven by a JAK2 V617F mutation in >95% of cases, leading to clonal erythroid expansion and markedly elevated thrombotic risk. Management centers on maintaining hematocrit <45% via phlebotomy, universal low-dose aspirin, and cytoreductive therapy for high-risk patients (age >60 or prior thrombosis). First-line cytoreduction is hydroxyurea; ropeginterferon alfa-2b and ruxolitinib are key alternatives. Untreated, 5-year mortality exceeds 50% from thrombosis; with modern therapy, median survival is ~17 years.

Overview and Recommendations

Background

•Polycythemia vera (PV) is a JAK2-driven myeloproliferative neoplasm defined by clonal expansion of hematopoietic stem cells, causing erythrocytosis, increased red cell mass, and a 5-fold elevated risk of arterial and venous thrombosis. The JAK2 V617F mutation, found in >95% of patients, constitutively activates JAK-STAT signaling, hypersensitizing progenitors to erythropoietin and driving trilineage hyperplasia.
•PV is the most common MPN, with an annual incidence of 0.5-4.0 per 100,000 and a prevalence of ~65,000 in the United States. Median age at diagnosis is 60-65 years; it is rare before age 40. A slight male predominance exists (M:F ~1.2:1). Survival has improved from 55% to 70% at 10 years over recent decades, but excess mortality persists (SMR ~1.6) driven by thrombosis (40-50% of deaths) and transformation to myelofibrosis or AML.
•The central molecular mechanism is constitutive JAK2 activation. In ~95% of cases, a valine-to-phenylalanine substitution at codon 617 (V617F) in the pseudokinase domain relieves autoinhibition. In the remaining 2-5%, JAK2 exon 12 mutations produce a similar phenotype, often with isolated erythrocytosis. Mutation order matters: when JAK2 V617F precedes TET2 mutation, the MPN phenotype is more aggressive with earlier diagnosis and higher hemoglobin levels.
•The natural history of PV progresses through three phases: (1) the polycythemic phase, erythrocytosis, often with leukocytosis and thrombocytosis; (2) post-PV myelofibrosis, bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms, occurring in 15-20% at 10 years; and (3) blast phase, transformation to AML or MDS, with a cumulative incidence of 5-10% at 20 years. The landmark CYTO-PV trial (2013) established that targeting hematocrit <45% halves the annual thrombosis rate (5.0% vs 1.1%) and is the foundation of modern management.

Evaluation

•Suspect PV in any patient with unexplained erythrocytosis (hemoglobin >16.5 g/dL in men, >16.0 g/dL in women; hematocrit >49% in men, >48% in women), especially when accompanied by splenomegaly, pruritus after warm baths, or a history of unprovoked thrombosis.
•Ask about headache, dizziness, fatigue, blurred vision, tinnitus, and paresthesias, all symptoms of hyperviscosity. Inquire specifically about aquagenic pruritus (intense itching after showering), a highly characteristic symptom reported in 30-50% of patients. Also ask about prior thrombotic events (stroke, MI, DVT, PE, splanchnic vein thrombosis) and bleeding (epistaxis, GI bleeding from platelet dysfunction).
•Examine for plethoric facies with ruddy cyanosis, conjunctival injection, retinal vein tortuosity, and splenomegaly (palpable in ~70%). Hepatomegaly is present in ~40%. Check for signs of hyperviscosity: neurologic deficits, papilledema, or focal findings from prior silent strokes. Measure blood pressure, hypertension is present in 30-50%.
•Order a complete blood count with differential. Classic PV shows erythrocytosis (Hb >16.5/16.0 g/dL), often with leukocytosis (WBC >11 × 10⁹/L in ~50%) and thrombocytosis (platelets >400 × 10⁹/L in ~40%). A normal WBC and platelet count does not exclude PV.
•Measure serum erythropoietin (EPO) level, a low EPO is a major WHO diagnostic criterion for PV. A normal or elevated EPO suggests secondary erythrocytosis (e.g., sleep apnea, COPD, high-altitude living, SGLT2 inhibitor use, or erythropoietin-secreting tumors).
•Perform JAK2 V617F mutation testing on peripheral blood or bone marrow as the initial molecular test. If negative, test for JAK2 exon 12 mutations. The variant allele frequency (VAF) of JAK2 V617F correlates with disease burden; a VAF >50% is associated with higher thrombotic risk and more pronounced erythrocytosis.
•Bone marrow biopsy with trephine core is mandatory for definitive diagnosis per WHO criteria. Key histologic findings: panmyelosis (hypercellular marrow with trilineage hyperplasia), pleomorphic megakaryocytes with hyperlobated nuclei ("staghorn" forms), and absent or minimal reticulin fibrosis (grade 0-1). Grade 2-3 fibrosis suggests primary myelofibrosis or masked PV.
•Apply the WHO diagnostic criteria: major criteria include hemoglobin >16.5/16.0 g/dL (or hematocrit >49%/48%), bone marrow panmyelosis, JAK2 mutation, and low serum EPO. Minor criteria: subnormal serum EPO level. Diagnosis requires all three major criteria or first two major plus the minor criterion.
•Exclude secondary causes of erythrocytosis: sleep apnea (polysomnography if suggested by snoring, daytime somnolence), chronic hypoxemia (pulse oximetry, arterial blood gas), high-affinity hemoglobin (Hb-oxygen dissociation curve), and erythropoietin-secreting tumors (renal cell carcinoma, cerebellar hemangioblastoma, hepatocellular carcinoma). Consider SGLT2 inhibitor use as a reversible cause.
•Assess thrombotic risk at diagnosis using the IWG-MRT risk stratification: low risk (age <60 and no prior thrombosis), high risk (age ≥60 or prior thrombosis). No formal intermediate-risk category exists in the classic two-tier system, though some guidelines recognize an intermediate group. Also calculate the QRISK3 score if age-appropriate, as a score >7.5% identifies additional high-risk patients.
•Also consider imaging for suspected thrombosis: CT/MR venography for abdominal or cerebral venous thrombosis; ultrasound for splenomegaly quantitation. Imaging is driven by clinical suspicion, not routine surveillance.

Management

•Initiate phlebotomy for all patients with hematocrit >45% regardless of risk status. Target hematocrit <45% (both sexes per CYTO-PV). Remove 300-500 mL of blood once or twice weekly until target is reached, then as needed to maintain target. Typical maintenance frequency is every 1-3 months.
•Start low-dose aspirin (81-100 mg PO daily) for all patients without contraindications (history of major bleeding, platelet count >1000 × 10⁹/L due to risk of acquired von Willebrand syndrome). The ECLAP trial demonstrated a 60% reduction in thrombotic events with aspirin.
•For high-risk patients (age ≥60 years or prior thrombosis), add cytoreductive therapy to phlebotomy and aspirin. First-line: 500 mg PO daily, titrated by 500 mg increments every 1-2 weeks to maintain hematocrit <45% and platelet count <400 × 10⁹/L. Typical maintenance dose: 500-2000 mg daily. Monitor CBC every 2-4 weeks during titration, then every 3 months.
•Alternative first-line for younger patients (age <50), those desiring pregnancy, or those with intolerance to hydroxyurea: 250 µg SC every 2 weeks, titrated to 500 µg SC every 2 weeks. Provides 70-80% complete hematologic response and reduces JAK2 VAF by 30-50% over 36 months (PROUD-CONTI study). 90 µg SC weekly, titrated to 180 µg weekly, is an alternative.
•For hydroxyurea-resistant or intolerant patients, switch to 10 mg PO twice daily. The RESPONSE trial showed 21% achieving hematocrit control with ≥35% spleen reduction at 32 weeks vs 1% with best available therapy (NNT = 5). The MAJIC-PV trial confirmed superior complete response (43% vs 26%). Monitor CBC, spleen size, and symptoms monthly initially.
•For phlebotomy-dependent patients who cannot tolerate or decline cytoreduction, consider (hepcidin mimetic) 40 mg SC weekly, titrated to 80 mg SC weekly. The REVIVE trial showed 60% achieved hematocrit control without phlebotomy vs 17% with placebo. This agent is investigational in the US; check local availability.
•Monitor for iron deficiency (ferritin <30 ng/mL) during chronic phlebotomy. Do not routinely replete iron, mild iron deficiency limits erythropoiesis and reduces phlebotomy frequency. Supplement iron only for symptomatic iron deficiency (fatigue, pica, restless legs) while monitoring hematocrit closely.
•Avoid combining aspirin with antiplatelet agents (clopidogrel, prasugrel) or anticoagulants (warfarin, DOACs) unless a separate thrombotic indication exists (e.g., atrial fibrillation, mechanical heart valve). The bleeding risk is high in PV due to platelet dysfunction.
•Do not administer cytoreductive therapy to low-risk patients unless they have severe symptoms (refractory pruritus, symptomatic splenomegaly) or require >6-8 phlebotomies per year. The NNT for cytoreduction to prevent one thrombosis in low-risk patients is ~50 over 5 years, making the risk-benefit unfavorable.
•Refer to a hematologist with expertise in MPNs at diagnosis for confirmation of risk stratification and initiation of cytoreductive therapy. Refer urgently for suspected disease transformation (worsening splenomegaly, cytopenias, ≥5% blasts on peripheral smear).
•Criteria to consider transition to post-PV myelofibrosis management (refer to MF protocols): new-onset splenomegaly, unexplained cytopenias (anemia, thrombocytopenia), constitutional symptoms (fevers, night sweats, weight loss), or rising reticulin fibrosis on repeat bone marrow biopsy.
•Discharge criteria for hospitalized patients with acute thrombosis: therapeutic anticoagulation established, hematocrit <45% (phlebotomy as needed), cytoreduction initiated if indicated, and follow-up with hematology within 2 weeks.

Board Review — High Yield

•JAK2 V617F mutation, present in >95% of PV; constitutive JAK-STAT activation; VAF correlates with disease burden and thrombotic risk.
•CYTO-PV trial, targeting hematocrit <45% reduces major thrombosis from 5.0% to 1.1% per year (NNT=6 over 3 years).
•ECLAP trial, low-dose aspirin (81-100 mg/day) reduces thrombotic events by 60% in PV.
•Aquagenic pruritus, pathognomonic symptom (30-50%); worse after warm bath; driven by histamine release from basophils.
•IWG-MRT risk stratification, two variables only: age ≥60 years and prior thrombosis; defines high-risk vs low-risk.
•Hydroxyurea, first-line cytoreduction for high-risk PV; reduces thrombosis but does not lower JAK2 VAF; risk of leg ulcers and potential leukemogenesis with >5 years use (NNH=22).
•Ropeginterferon alfa-2b, first-line for younger patients; achieves molecular response (30-50% JAK2 VAF reduction); preferred in pregnancy.
•Ruxolitinib, second-line for HU-resistant/intolerant; RESPONSE trial (N=222) showed 21% hematocrit control + spleen reduction; monitor for herpes zoster reactivation.
•Post-PV myelofibrosis, 15-20% at 10 years; diagnosed by bone marrow fibrosis, cytopenias, splenomegaly; use DIPSS/DIPSS-plus for prognosis.
•Serum erythropoietin, low in PV (major diagnostic criterion); normal or high suggests secondary erythrocytosis.

Deep Dive — Evidence Details

Definition and Epidemiology

▸Polycythemia vera is a clonal hematopoietic stem cell neoplasm defined by JAK2 mutation in >95% of cases, leading to erythrocytosis and increased thrombotic risk.
▸Annual incidence ranges from 0.5 to 4.0 per 100,000, with a median age at diagnosis of 60-65 years and a slight male predominance.
▸Median survival is approximately 17 years, but remains significantly reduced compared to the general population, with thrombosis as the leading cause of death.

HY High Yield: PV is the most common MPN; remember that >95% of patients carry a JAK2 mutation, and diagnostic thresholds for hemoglobin/hematocrit differ by sex (men >16.5 g/dL, women >16.0 g/dL) [12, 16].

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic stem cell expansion driven by a gain-of-function mutation in the JAK2 gene, leading to erythrocytosis, increased red cell mass, and elevated thrombotic risk ^[16]^D5.

Also Called / Synonyms

Polycythemia rubra vera
Primary polycythemia
Vaquez disease
Osler-Vaquez disease
PV (abbreviation)

Key Terms Used in This Article

Polycythemic phase: The initial chronic phase with erythrocytosis, often with leukocytosis and thrombocytosis, and without significant bone marrow fibrosis.
Post-PV myelofibrosis (post-PV MF): A late-stage evolution characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms, occurring in approximately 10-20% of patients after 10-15 years ^[8]^B2b.
Blast phase (BP): Transformation to acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), with a cumulative incidence of about 5-10% at 20 years ^[8]^B2b.
JAK2 V617F variant allele frequency (VAF): The proportion of mutated JAK2 alleles in peripheral blood or bone marrow, used as a biomarker of clonal burden and disease activity ^[10]^D5.

Classification of Variants

PV is classified by JAK2 mutation status:

JAK2 V617F-positive: >95% of patients harbor this exon 14 mutation ^[16]^D5.
JAK2 exon 12 mutation-positive: A small subset (2-5%) with mutations in exon 12, often presenting with isolated erythrocytosis and lower leukocyte counts.
JAK2 wild-type: Extremely rare; diagnosis requires rigorous exclusion of secondary erythrocytosis and other MPNs ^[11]^D5.

Clinical Significance

PV is the most common MPN, with an annual incidence of 0.5 to 4.0 per 100,000 persons in the United States and a prevalence of approximately 65,000 affected individuals ^[16]^D5. It is associated with a substantial burden of thrombotic events, disease transformation, and reduced life expectancy.

PV incidence increases with age, with a median age at diagnosis of 60-65 years; it is uncommon before age 40, though pediatric cases occur ^[5]^B3b^[16]^D5. A slight male predominance is observed (male-to-female ratio ~1.2:1) ^[12]^D5^[16]^D5. Geographic variation exists, with higher reported rates in North America and Europe compared with Asia, though diagnostic practices may contribute ^[15]^D5.

Survival has improved over time: in a Swedish population-based study, relative survival at 10 years increased from 55% in 1973-1982 to 70% in 1998-2008 ^[6]^B2b. Median survival in contemporary cohorts is approximately 17 years overall, but remains significantly lower than the age-matched general population (excess mortality rate ratio ~1.6) ^[1]^A1b^[6]^B2b. The leading causes of death are thrombosis (40-50%), transformation to AML/MDS (10-15%), and post-PV MF complications ^[8]^B2b^[16]^D5.

Pearl: Polycythemia vera is a JAK2-driven MPN with an incidence of 0.5-4.0/100,000, a median survival of ~17 years, and a persistent excess mortality driven by thrombosis and disease transformation ^[1]^A1b^[6]^B2b^[16]^D5.

Risk Factors and Prevention

▸Age >60 years and prior thrombosis are the dominant clinical risk factors for thrombosis in PV, defining high-risk disease.
▸Hydroxyurea exposure beyond 5 years is associated with an increased risk of AML/MDS transformation (OR 2.7, NNH 22).
▸No population-based screening for PV is currently recommended; the TRAKJAK score can guide selective JAK2 testing in erythrocytosis.

HY High Yield: The QRISK3 score (>7.5% threshold) often outperforms traditional age/thrombosis-based risk stratification in PV, especially in younger low-risk patients [28].

Several well-defined risk factors drive both the development of polycythemia vera (PV) and its primary complication, thrombosis. The most firmly established risk factor for acquiring PV is age: incidence rises sharply after age 60, with a median age at diagnosis of approximately 65 years ^[17]^D5. Sex plays a lesser role, with a slight male predominance (male-to-female ratio ~1.2:1) ^[23]^B2b.

Genetic and Acquired Risk Factors

The strongest genetic predisposing factor is a variant in the JAK2 gene, specifically the single-nucleotide polymorphism rs10974944, which is associated with both JAK2 V617F-positive and V617F-negative MPNs (OR 2.1, 95% CI 1.4-3.2) ^[21]^B3b. The somatic JAK2 V617F mutation itself is the defining molecular driver of PV, found in ~95% of cases ^[11]^D5^[26]^D5. A family history of MPN confers a 5- to 7-fold increased risk in first-degree relatives, although absolute incidence remains low ^[17]^D5.

Thrombotic Risk Factors

Thrombotic risk stratification in PV relies on two classic clinical variables, age >60 years and prior thrombosis, which together define high-risk disease ^[17]^D5^[22]^B2b. Additional thrombotic risk factors include:

Risk Factor	Estimated RR/OR	Evidence Level
Age >60 years	RR ~2.5	Category 1 ^[17]^D5
Prior thrombosis	RR ~3.0	Category 1 ^[17]^D5
	OR 1.8	2b ^[22]^B2b^[28]^B3b
Diabetes mellitus	OR 1.5	2b ^[28]^B3b
Smoking	OR 1.6	2b ^[28]^B3b
QRISK3 score >7.5%	HR 2.1	3b ^[28]^B3b
Elevated calprotectin	OR 2.3 per SD	2b ^[24]^B2b

Importantly, novel biomarkers of thromboinflammation, particularly elevated levels of calprotectin (S100A8/A9) and tissue factor, are associated with high-risk thrombosis scores in newly diagnosed, treatment-naïve patients (OR 2.3 per SD, p<0.01) ^[24]^B2b. The QRISK3 score, a cardiovascular risk calculator validated in the general population, outperforms conventional two-tiered risk stratification (age/thrombosis) in identifying high-risk PV patients, with a threshold of >7.5% predicting a 2.1-fold increased hazard of thromboembolic events ^[28]^B3b.

Treatment-Related Risk Factors for Malignant Transformation

Cytoreductive therapy itself carries risks. In a population-based nested case-control study, use of hydroxyurea (HU) was associated with a significantly increased odds of transformation to acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) when cumulative exposure exceeded 5 years (OR 2.7, 95% CI 1.2-5.7; NNH = 22 over 5 years) ^[19]^B3b. This risk appears greatest in patients exposed to multiple therapies, including HU followed by radioactive phosphorus or alkylating agents ^[19]^B3b. Notably, interferon-alfa has not been linked to increased leukemogenesis in PV studies ^[20]^A1b^[23]^B2b. The cumulative incidence of AML/MDS transformation at 10 years is approximately 5-10%, with risk rising steadily with both age and disease duration ^[8]^B2b.

Prevention and Screening

No primary prevention strategy exists to prevent PV onset. However, secondary prevention of thrombosis is the cornerstone of . NCCN recommends that all PV patients undergo baseline with aggressive management of modifiable risk factors (hypertension, diabetes, smoking, dyslipidemia) ^[17]^D5. For low-risk patients (age ≤60 years, no prior thrombosis), phlebotomy to maintain hematocrit <45% plus low-dose (81-100 mg daily) is the standard to reduce thrombotic events ^[17]^D5^[20]^A1b. Screening for PV in the general population using JAK2 mutation testing is not recommended by the USPSTF or NCCN, as the low prevalence (1-2 per 100,000) and lack of proven benefit from earlier detection do not support population-level screening ^[17]^D5. The TRAKJAK score, a prediction model based on parameters (hemoglobin, white blood cell count, platelet count) and serum erythropoietin, can help select patients with erythrocytosis who warrant JAK2 mutation testing, reducing unnecessary screening costs ^[27]^B3b.

Pearl: Prevention in PV focuses exclusively on mitigating thrombotic risk through hematocrit control (<45%), low-dose aspirin, and cardiovascular risk factor modification, rather than primary prevention of the disease itself ^[17]^D5^[28]^B3b.

Histopathology and Molecular Biology

▸JAK2 V617F mutation in exon 14 is present in ~95% of PV; exon 12 mutations account for most of the remainder.
▸Bone marrow histology shows trilineage hyperplasia with pleomorphic megakaryocytes and absent/minimal reticulin fibrosis.
▸Mutation order (JAK2 before TET2) is associated with a more aggressive phenotype, though not yet used in clinical decision-making.

HY High Yield: JAK2 V617F homozygosity (via 9p uniparental disomy) is a hallmark of PV and correlates with higher hemoglobin and leukocyte counts [30, 47].

The clonal expansion in polycythemia vera (PV) is driven by a constitutively active JAK-STAT signaling pathway, most commonly from a point mutation in the pseudokinase domain of JAK2 (V617F) that relieves autoinhibition, leading to cytokine-independent proliferation of erythroid progenitors ^[30]^C4^[34]^D5. This mutation is present in approximately 95% of PV cases; the remaining 5% harbor activating mutations in JAK2 exon 12, which similarly dysregulate signaling and produce an indistinguishable clinical phenotype ^[38]^D5^[47]^D5. The consequence is a marked expansion of the erythroid lineage, with variable involvement of granulocytic and megakaryocytic compartments, reflected in the characteristic bone marrow histology.

Bone Marrow Histology

The diagnostic bone marrow biopsy in PV shows hypercellularity (age-adjusted) with trilineage hyperplasia, most prominently erythroid. Megakaryocytes are increased and appear pleomorphic, with a spectrum of sizes including large forms with hyperlobulated nuclei, but without the dense clustering or marked atypia seen in primary myelofibrosis ^[42]^D5^[43]^D5. Reticulin fibrosis is absent or minimal at diagnosis; its presence suggests progression to post-PV myelofibrosis. The WHO classification emphasizes that histology, combined with JAK2 mutation status and low serum erythropoietin, distinguishes PV from secondary erythrocytosis and other MPNs ^[42]^D5^[43]^D5.

Molecular Drivers and Clonal Architecture

JAK2 V617F is a gain-of-function mutation in exon 14 that renders the kinase constitutively active, hypersensitizing hematopoietic progenitors to erythropoietin and other cytokines ^[33]^D5^[34]^D5. In a knockin mouse model, physiological expression of Jak2V617F produced a lethal MPN recapitulating human PV, with the hematopoietic stem cell (HSC) compartment initiating disease but myeloid progenitors driving erythroid expansion ^[33]^D5. The mutation is often homozygous in PV due to mitotic recombination on chromosome 9p, and the variant allele frequency (VAF) correlates with disease phenotype: higher VAF is associated with more pronounced erythrocytosis, leukocytosis, and splenomegaly ^[30]^C4^[47]^D5.

Mutation order significantly influences disease presentation. In patients where JAK2 V617F is acquired before a mutation in TET2 (a tumor suppressor involved in DNA demethylation), the MPN phenotype is more pronounced, with earlier age at diagnosis and higher hemoglobin levels ^[31]^C4. Conversely, when TET2 mutation precedes JAK2, the disease tends to be more indolent ^[31]^C4. Additional cooperating mutations in genes such as DNMT3A, ASXL1, and IDH1/2 are less common in PV than in myelofibrosis but contribute to clonal evolution and risk of leukemic transformation ^[36]^D5^[44]^B3b. The mutational landscape of PV is relatively simple compared to other myeloid malignancies, with a median of 1-2 driver mutations per patient ^[36]^D5.

Pathogenic Mechanisms and Clinical Correlates

Constitutive JAK-STAT signaling not only drives proliferation but also alters the bone marrow microenvironment. Neutrophilic granulocytes in PV exhibit increased adhesion to endothelium and release of inflammatory mediators, promoting a prothrombotic state ^[35]^D5. The JAK2 V617F mutation also enhances platelet activation and interaction with leukocytes, contributing to the high risk of arterial and venous thrombosis ^[35]^D5^[46]^D5. In patients with splanchnic vein thrombosis, JAK2 V617F is found at low VAF (<10%), suggesting that even a small mutant clone can predispose to thrombosis ^[46]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Role of mutation order in clinical	Some experts argue that mutation order (JAK2 vs TET2) should inform risk stratification ^[31]^C4	Current guidelines (WHO, NCCN) do not incorporate mutation order into treatment decisions ^[43]^D5	Weak; based on retrospective data	Mutation order is not yet used to guide therapy but may explain phenotypic variability

Pearl: The JAK2 V617F mutation is the central driver in >95% of PV cases, and its variant allele frequency, along with mutation order relative to TET2, influences disease severity and thrombotic risk ^[30]^C4^[31]^C4^[47]^D5.

Key Molecular Drivers in Polycythemia Vera

Mutation	Frequency	Functional Consequence	Clinical Association
JAK2 V617F (exon 14)	~95%	Constitutive JAK-STAT activation	Erythrocytosis, leukocytosis, thrombosis
JAK2 exon 12 mutations	~5%	Similar JAK-STAT activation	Indistinguishable from V617F-positive PV
TET2 mutations	~10-15% (co-occurring)	Impaired DNA demethylation	May modify phenotype; earlier mutation order linked to indolent disease
DNMT3A mutations	~5%	Altered DNA methylation	Associated with clonal hematopoiesis; may increase risk of transformation

Data from ^[31]^C4^[36]^D5^[38]^D5^[44]^B3b^[47]^D5

Clinical Presentation

▸Headache, pruritus, and fatigue are the most common early symptoms, while thrombotic events (arterial > venous) are the hallmark complication.
▸Splanchnic vein thrombosis is a distinctive presenting feature in 5-10% of patients, often in younger individuals.
▸Physical examination reveals plethoric facies, splenomegaly, and hypertension in the majority of patients.

HY High Yield: Splanchnic vein thrombosis (Budd-Chiari syndrome, portal vein thrombosis) is a classic presenting feature of PV in young patients; always check JAK2 mutation in unexplained splanchnic thrombosis [62].

The clinical presentation of polycythemia vera is dominated by symptoms of hyperviscosity and thrombosis, but a substantial minority of patients are diagnosed incidentally on routine blood counts ^[49]^A1c^[67]^D5. Symptoms evolve insidiously over months to years, with the median age at diagnosis of 60 years and a slight male predominance ^[63]^B3b^[67]^D5.

Presenting Symptoms

Headache, dizziness, fatigue, and pruritus (especially after a warm bath) are the most common early complaints, reported in 30-50% of patients ^[60]^B2b^[67]^D5. Pruritus is often severe and refractory, driven by histamine release from basophils. , burning pain and erythema of the hands or feet, occurs in 5-10% and is a microvascular thrombotic phenomenon ^[56]^D5. Visual disturbances (blurred vision, scotomata, transient monocular blindness) reflect retinal hyperviscosity. Thrombotic events are the hallmark complication: arterial thrombosis (stroke, myocardial infarction) in 30-40% and venous thrombosis (deep vein thrombosis, pulmonary embolism, splanchnic vein thrombosis) in 15-25% ^[62]^B3b^[67]^D5. Splanchnic vein thrombosis, including Budd-Chiari syndrome, is a distinctive presenting feature in 5-10% of patients, often in younger individuals ^[62]^B3b. Bleeding manifestations (epistaxis, bleeding) occur in 10-20% due to platelet dysfunction ^[56]^D5.

Physical Examination Findings

Plethoric facies with ruddy cyanosis is the classic finding, present in 60-70% of patients at diagnosis ^[67]^D5. Conjunctival injection and retinal vein tortuosity are common. Splenomegaly is palpable in 70% of patients, and hepatomegaly in 40% ^[49]^A1c^[56]^D5. is present in 30-50% due to increased blood volume ^[67]^D5. Neurologic examination may reveal subtle cognitive impairment or focal deficits from prior silent strokes.

Phenotypic Variants

Variant	Key Features	Frequency
JAK2 V617F	Classic PV: panmyelosis, high thrombotic risk, splenomegaly	95% of PV ^[59]^D5
JAK2 exon 12	Younger age, isolated erythrocytosis, lower leukocytosis/thrombocytosis, less splenomegaly	3-5% ^[65]^B3b
JAK2-unmutated	Requires exclusion of secondary erythrocytosis; often normal EPO	<1% ^[11]^D5^[26]^D5

Red Flags

Acute thrombotic event (stroke, MI, pulmonary embolism) requires urgent cytoreduction and anticoagulation. Severe headache with visual changes or abdominal pain suggests hyperviscosity or splanchnic thrombosis. Hematocrit >55% is associated with exponentially increased thrombotic risk ^[67]^D5.

Atypical Presentations

Asymptomatic patients discovered on routine labs account for 15-20% of diagnoses ^[57]^C4. Splanchnic vein thrombosis may be the first manifestation, especially in young women ^[62]^B3b. Ocular involvement, conjunctival hyperemia, episcleral vascular tortuosity, , can precede systemic diagnosis ^[70]^C4.

Pearl: The most common presenting symptom is headache, but the most dangerous is thrombosis; a high index of suspicion for splanchnic vein thrombosis is warranted in young patients with abdominal pain and unexplained erythrocytosis ^[62]^B3b^[67]^D5.

Biopsy and Histologic Diagnosis

▸Bone marrow trephine biopsy is required for WHO diagnosis of PV; aspirate alone is inadequate.
▸Panmyelosis with atypical hyperlobated megakaryocytes and reticulin grade 0-1 are the essential histologic features.
▸JAK2 V617F is detectable in marrow cores of 87% of PV patients using PCR-based assays with a 5% detection threshold.

Dx Diagnostic Essentials: Gold-standard test: Trephine core biopsy showing panmyelosis with pleomorphic, hyperlobated megakaryocytes and reticulin grade 0-1, plus JAK2 V617F mutation detection.

HY High Yield: Reticulin grade is the dominant independent predictor of WHO diagnostic category among MPNs, always report it [72].

Bone marrow biopsy is the gold-standard diagnostic test for Polycythemia Vera (PV), providing the histologic framework that distinguishes PV from other myeloproliferative neoplasms (MPNs) and reactive erythrocytosis ^[72]^C4^[75]^D5. The biopsy must be a trephine core of at least 1.5 cm in length, fixed in B5 or formalin, and decalcified in EDTA to preserve DNA integrity for downstream JAK2 mutation testing ^[73]^C4. Aspirate alone is insufficient; only the intact core biopsy allows reliable assessment of cellularity, megakaryocyte morphology, and reticulin fibrosis ^[75]^D5.

Histologic Hallmarks

The diagnostic triad on biopsy in PV is: (1) panmyelosis - hypercellular marrow (age-adjusted cellularity ≥80% in patients <60 years, ≥60% in those ≥60 years) with trilineage hyperplasia; (2) atypical megakaryocytes - increased numbers of large, hyperlobated ("staghorn") forms often in loose clusters, as opposed to the tight clusters seen in primary myelofibrosis; and (3) absent or minimal reticulin fibrosis (grade 0-1 on the EUMNET scale) ^[74]^A1c^[75]^D5^[79]^B3b. Reticulin grading is the single strongest independent predictor of WHO diagnostic category among MPNs ^[72]^C4. Grade 2-3 fibrosis at presentation argues against PV and suggests either early primary myelofibrosis or post-PV myelofibrosis ^[74]^A1c^[75]^D5.

JAK2 Mutation Detection

Bone marrow trephine specimens permit reliable detection of the JAK2 V617F mutation using the TaqMan PCR SNP genotyping assay, which can identify the mutation when it is present in as few as 5% of cells ^[73]^C4. Among PV patients, JAK2 V617F is detected in 87% of marrow cores ^[73]^C4. For the rare JAK2 exon 12 mutations, a dedicated PCR or next-generation sequencing panel is required; bone marrow DNA is preferred because it contains the malignant clone at higher allele burden than peripheral blood ^[79]^B3b. If a mutation is not found, the diagnosis of PV should be reconsidered.

When Biopsy Is Required

Biopsy is mandatory in all suspected PV per WHO criteria, but it can be deferred briefly in patients with classic triad (erythrocytosis, JAK2 mutation, low serum erythropoietin) if an urgent cytoreductive therapy is needed. The biopsy confirms the WHO morphologic subtype (PV, primary myelofibrosis, or ) and provides a baseline reticulin grade that is critical for detecting later progression to post-PV myelofibrosis ^[75]^D5^[74]^A1c. In cases where the peripheral blood JAK2 test is negative but clinical suspicion remains high, biopsy is essential to exclude early myelofibrosis or reactive causes ^[72]^C4.

Pitfalls and Handling

Do not submit bone marrow for flow cytometry unless acute leukemia is suspected - PV cells lack a distinctive immunophenotype. Ensure that a portion of the core (a 2-3 mm segment) is snap-frozen for molecular studies if JAK2 testing will be performed on the biopsy rather than blood ^[73]^C4. The aspirate smear can confirm the presence of iron stores; absent iron stores in the marrow support the diagnosis and may predict a better response to phlebotomy.

Pearl: A core biopsy showing panmyelosis with pleomorphic, hyperlobated megakaryocytes and grade 0-1 reticulin, coupled with JAK2 V617F positivity, is diagnostic of PV in >95% of cases; the presence of grade 2-3 fibrosis should prompt workup for primary myelofibrosis or masked PV ^[75]^D5^[79]^B3b.

Imaging

▸No imaging modality is needed for PV diagnosis; imaging targets thrombotic complications (CVT, PVT, stroke) and splenomegaly.
▸Contrast-enhanced CT or MR venography is first-line for suspected abdominal or cerebral vein thrombosis.
▸Splenomegaly is best assessed by ultrasound (clinical practice) or MRI (trial context); liver lesions in Budd-Chiari syndrome often require biopsy to exclude malignancy.

HY High Yield: For any patient with cryptogenic thrombosis (especially cerebral or splanchnic), test for JAK2 V617F, PV can present as occult thrombosis up to 3 years before hematologic abnormalities appear.

Imaging in polycythemia vera (PV) serves three distinct roles: identifying thrombotic complications, evaluating splenomegaly and liver abnormalities, and ruling out occult malignancy that might masquerade as secondary erythrocytosis. No imaging modality is required for the diagnosis of PV itself, which rests on hematologic and molecular criteria (see prior sections). However, once the diagnosis is established, targeted imaging is essential for managing the major sources of morbidity.

Screening for Thrombotic Events

Thrombosis is the dominant complication of PV, and imaging is indicated when symptoms suggest an acute event. Cerebral venous sinus thrombosis (CVST) and stroke are the most frequent neurologic presentations ^[84]^D5^[85]^C4. For suspected CVST, MR venography (or CT venography if MRI is unavailable) is the initial test of choice. In patients with embolic stroke of undetermined source, JAK2 V617F testing should be considered, as PV can present with stroke 2-3 years before overt hematologic manifestations ^[84]^D5^[85]^C4. For abdominal thromboses, portal vein thrombosis (PVT) and Budd-Chiari syndrome, contrast-enhanced CT or MRI with venography of the portal and hepatic veins is first-line. Up to 10-15% of PV patients develop PVT, and prompt detection enables early anticoagulation and, in select cases, catheter-directed thrombolysis ^[83]^C4. Spinal cord infarction, though rare, should be assessed with diffusion-weighted MRI; it may be accompanied by aortic thrombus on CT angiography ^[86]^C4.

Assessing Splenomegaly and Liver Lesions

Splenomegaly is present in approximately 30-40% of PV patients at diagnosis and may progress to massive enlargement. Ultrasound is the most practical initial test, providing reproducible measurements of spleen length (normal ≤ 12 cm in the coronal plane). MRI or CT offers more accurate volumetric assessment when precise monitoring is needed, such as in clinical trials or when planning cytoreductive therapy. In patients with Budd-Chiari syndrome (which complicates PV in ≤5%), multiple benign hepatic nodules, focal nodular hyperplasia (FNH) or nodular regenerative hyperplasia (NRH), can develop. These lesions may be difficult to distinguish radiologically from hepatocellular carcinoma or metastases; biopsy is required when imaging is indeterminate ^[78]^C4.

Functional Imaging and Special Scenarios

In patients with neurologic symptoms such as chorea or migraine, FDG PET/CT and dopamine transporter SPECT have demonstrated reversible abnormalities in corticobasal ganglia metabolism and dopaminergic function that normalize after hematocrit correction. These findings are not routine but help confirm a functional, reversible pathophysiology ^[87]^C4^[88]^C4. For patients with persistent abdominal symptoms, transcranial Doppler may detect microembolic signals in intracranial arteries, which can disappear after hematocrit is controlled ^[85]^C4.

Controversies and Guideline Disagreement

No major guideline disagreement exists regarding imaging in PV; however, the NCCN and European LeukemiaNet both emphasize that imaging is driven by clinical suspicion of thrombosis, not routine surveillance. The optimal imaging modality for splenomegaly follow-up is also not standardized, ultrasound is preferred for cost and accessibility, while MRI is reserved for research or when precise volume is needed.

Question	Position A (NCCN)	Position B (ELN)	Strength	Implication
Routine imaging for extramedullary hematopoiesis?	Not recommended outside of symptoms	Same	Consistent	Imaging is symptom-driven
Best modality for splenomegaly follow-up	Ultrasound	Ultrasound or MRI	Largely consistent	No consensus on volumetric MRI superiority

Pearl: In PV, imaging is a tool for complication detection, not diagnosis, always interpret findings in context of JAK2 mutation status and hematocrit, and consider occult PV in cryptogenic thrombosis, as early JAK2 testing can prevent recurrent events ^[84]^D5^[85]^C4.

Imaging Indications in Polycythemia Vera

Indication	First-line Modality	Key Finding	Notes
Suspected cerebral venous sinus thrombosis	MR venography (or CT venography)	Filling defect in dural sinuses	JAK2 testing indicated if stroke of unknown source
Suspected portal vein thrombosis	Contrast-enhanced CT or MRI	Portal vein filling defect or cavernous transformation	Up to 10-15% of PV patients
Budd-Chiari syndrome	Contrast-enhanced CT or MRI with venography	Hepatic vein occlusion or thrombosis	Evaluate for benign regenerative nodules (FNH/NRH)
Splenomegaly	Ultrasound (coronal length > 12 cm)	Enlarged spleen	MRI for volumetric assessment in trials
Chorea or atypical headache	FDG PET/CT, dopamine transporter SPECT	Reversible basal ganglia hypermetabolism	Not routine; research setting only

Molecular Diagnostics and Biomarkers

▸JAK2 V617F mutation is present in ~95% of PV cases; JAK2 exon 12 mutations account for most of the remainder.
▸Additional mutations in SRSF2, IDH1/2, EZH2, NFE2, or ≥2 non-driver mutations define a PV high molecular risk (PV-HMR) category that predicts hematologic evolution.
▸Molecular testing is essential for diagnosis; cytogenetic abnormalities are less common but may be relevant in suspected progression.

HY High Yield: In JAK2-negative suspected PV, always test for JAK2 exon 12 mutations and consider secondary causes of erythrocytosis before labeling as idiopathic.

Detection of a JAK2 mutation is the molecular cornerstone of polycythemia vera diagnosis, with the JAK2 V617F point mutation present in approximately 95% of cases and JAK2 exon 12 mutations accounting for most of the remainder ^[59]^D5^[91]^A1a. Current guidelines recommend JAK2 mutation testing as the initial molecular test in suspected PV ^[59]^D5. The JAK2 V617F allele burden is typically higher in PV than in and correlates with the degree of erythrocytosis and risk of thrombosis ^[59]^D5. In the small fraction of patients who test negative for both V617F and exon 12 mutations, the diagnosis of PV should be reconsidered, and secondary causes of erythrocytosis, such as sleep apnea, high-altitude exposure, or use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, should be thoroughly investigated ^[98]^B2b.

Additional Mutations and Molecular Risk Stratification

Beyond the canonical JAK2 driver, approximately 53% of PV patients harbor at least one additional mutation in genes involved in epigenetic modification, DNA methylation, mRNA splicing, or transcriptional regulation ^[94]^B2b. A recent multicenter study identified a PV high molecular risk (PV-HMR) category defined by mutations in SRSF2, IDH1/2, EZH2, or NFE2, the presence of copy number variations, or carrying two or more non-driver mutations ^[94]^B2b. PV-HMR is independently associated with a significantly higher risk of hematologic evolution to myelofibrosis or blast phase, and its incorporation into prognostic models may refine risk stratification beyond the conventional three-tier system ^[69]^D5^[94]^B2b. Mutations in ASXL1, TET2, and DNMT3A are also recurrent but have less consistent prognostic impact in PV compared with myelofibrosis ^[59]^D5^[69]^D5.

Cytogenetic Abnormalities

Conventional cytogenetic abnormalities are less common in PV than in myelofibrosis, occurring in approximately 10-15% of patients at diagnosis, with +8, +9, del(20q), and del(13q) being the most frequent ^[59]^D5. Array comparative genomic hybridization plus single nucleotide polymorphism (aCGH+SNP) analysis can detect cryptic alterations, such as 12q14.3 deletions involving HMGA2, which are associated with more aggressive disease but are rarely found in PV compared with myelofibrosis ^[95]^B2b. Cytogenetic analysis is not required for routine diagnosis but may be considered when disease progression is suspected ^[97]^B3b.

Emerging Biomarkers

Circulating procoagulant microparticles expressing tissue factor are elevated in PV and correlate with thrombotic risk, offering a potential biomarker for thromboprophylaxis decisions ^[90]^B2b. Neutrophil extracellular trap (NET) formation and elevated circulating nucleosomes have also been described, though their clinical utility remains investigational ^[92]^B2b. Immunoregulatory B-cell phenotypes, including PD-L1+ and IL-10-producing subsets, are altered in MPNs and may be modulated by ruxolitinib or interferon-α2 therapy, but these findings have not yet entered routine practice ^[89]^A1b.

Pearl: JAK2 V617F mutation testing is the first-line molecular diagnostic test for suspected polycythemia vera; absence of V617F should prompt testing for JAK2 exon 12 mutations. Additional mutations in epigenetic modifiers and spliceosome genes, particularly SRSF2, IDH1/2, EZH2, and NFE2, define a high molecular risk category associated with increased risk of leukemic transformation ^[94]^B2b.

Staging

▸PV staging uses the IWG-MRT risk score, classifying patients as low, intermediate, or high risk based on age ≥ 60 years and prior thrombosis
▸High-risk patients (age ≥ 60 years and prior thrombosis) have a ~25-35% 5-year thrombosis risk and require cytoreductive therapy

HY High Yield: In PV, staging is risk stratification, not anatomic. The only two variables needed for the core risk score are age ≥ 60 years and prior thrombosis. Memorize these thresholds, they dictate the need for cytoreduction.

Polycythemia Vera is not staged by the traditional or anatomic systems used for solid tumors. Instead, risk stratification serves as the functional staging framework, directing all decisions. The most widely adopted system is the revised International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) score, which categorizes patients into low-, intermediate-, and high-risk groups based on two clinical variables: age ≥ 60 years and history of thrombosis ^[100]^B2b^[106]^B2c.

Risk Stratification Categories

Risk Category	Criteria	Estimated 5-Year Thrombosis Risk	Recommended Initial Management
Low risk	Age < 60 years AND no prior thrombosis	~5-10%	Phlebotomy + low-dose (75-100 mg daily)
Intermediate risk	Age ≥ 60 years OR prior thrombosis	~15-20%	Phlebotomy + aspirin; consider cytoreduction based on individual factors
High risk	Age ≥ 60 years AND prior thrombosis	~25-35%	Phlebotomy + aspirin + cytoreductive therapy (hydroxyurea or interferon)

Bold key thresholds: Age ≥ 60 years and prior thrombosis are the two dominant determinants of thrombotic risk. Patients in the high-risk category have a 3- to 5-fold higher annual incidence of major cardiovascular events compared with low-risk patients ^[100]^B2b^[106]^B2c.

Molecular and Hematologic Modifiers

While the IWG-MRT score remains the clinical cornerstone, emerging evidence highlights additional risk modifiers. A JAK2 V617F allele burden > 50% has been associated with higher hematocrit, greater splenomegaly, and increased thrombotic risk, though it is not yet incorporated into formal staging algorithms ^[102]^C4^[105]^D5. Leukocytosis (WBC > 11 × 10⁹/L) at diagnosis is an independent predictor of thrombosis, particularly for arterial events ^[100]^B2b. Persistent thrombocytosis (platelet count > 1000 × 10⁹/L) may paradoxically increase hemorrhagic risk from , complicating aspirin use.

Post-Polycythemia Vera Myelofibrosis (Post-PV MF)

A distinct staging framework applies when PV transforms into post-PV MF. The Dynamic International Prognostic Scoring System (DIPSS) and its plus version (DIPSS-plus) incorporate age, hemoglobin, leukocyte count, circulating blasts, constitutional symptoms, and karyotype. The DIPSS-plus assigns 1 point each for age > 65 years, hemoglobin < 10 g/dL, leukocytes > 25 × 10⁹/L, blasts ≥ 1%, and constitutional symptoms; karyotype adds 1 point for unfavorable findings. This system stratifies median survival from 185 months (low risk) to 16 months (very high risk) ^[104]^D5^[107]^C4.

Clinical Application

Risk stratification should be performed at diagnosis and reassessed whenever a thrombotic event occurs or significant clinical deterioration arises. The score directly determines whether to initiate cytoreduction: in low-risk patients, the NNT for cytoreduction to prevent one thrombosis over 5 years is approximately 50, while in high-risk patients the NNT drops to ~8 ^[100]^B2b.

Pearl: In Polycythemia Vera, staging is clinical risk stratification based on age ≥ 60 years and prior thrombosis, these two variables alone determine the need for cytoreductive therapy, which reduces thrombotic events with an NNT of ~8 in high-risk patients ^[100]^B2b.

Management Overview

▸Management is risk-stratified: low-risk (age ≤60, no thrombosis) receives phlebotomy + aspirin; high-risk adds cytoreduction.
▸Target hematocrit <45% is based on the CYTO-PV trial (NNT=6 to prevent one major thrombotic event).
▸Hydroxyurea is first-line cytoreduction; ropeginterferon and ruxolitinib are effective second-line options with molecular response data.

Rx Drug of Choice: First-line cytoreduction: **hydroxyurea 500-1000 mg PO daily** for high-risk patients [49]. For HU-intolerant/resistant patients: **ruxolitinib 10 mg PO BID** [113].

! Warning: Do not use hydroxyurea during pregnancy; switch to interferon alfa. Avoid aspirin if platelet count >1000 × 10⁹/L due to bleeding risk [49][111].

of polycythemia vera rests on three pillars: phlebotomy to maintain hematocrit below 45%, low-dose for thromboprophylaxis, and cytoreductive therapy for high-risk patients ^[49]^A1c^[111]^A1c. The goal is to reduce thrombotic risk, control symptoms, and prevent disease transformation. Detailed protocols for each modality are covered in dedicated child pages; this section provides the overarching framework.

Step 1: Risk Stratification

Risk assessment determines the intensity of therapy. The NCCN and ELN define high-risk as age >60 years or prior thrombosis; all others are low-risk ^[49]^A1c^[111]^A1c. The CYTO-PV trial (N=365) established that maintaining hematocrit <45% reduces the primary composite endpoint of cardiovascular death or major thrombosis from 48% to 32% (HR 0.67, 95% CI 0.52-0.85; NNT = 6) ^[2]^A1b. This threshold applies to both sexes.

Step 2: Phlebotomy and Aspirin

All patients with hematocrit >45% should undergo phlebotomy to achieve and maintain the target. Low-dose aspirin (81-100 mg daily) is recommended for all patients without contraindications, based on the ECLAP trial showing a 60% reduction in thrombotic events ^[49]^A1c^[111]^A1c. Aspirin is particularly important in high-risk patients.

Step 3: Cytoreduction for High-Risk Patients

Cytoreductive therapy is indicated for high-risk patients and those with symptomatic splenomegaly, severe pruritus, or poor phlebotomy tolerance ^[49]^A1c^[111]^A1c. First-line options include:

Hydroxyurea (HU) 500-1000 mg daily, titrated to maintain hematocrit <45% and platelet count <400 × 10⁹/L. HU reduces thrombotic events but does not modify the JAK2 allele burden ^[1]^A1b^[49]^A1c.
Ropeginterferon alfa-2b 250-500 µg subcutaneously every 2 weeks, achieving complete hematologic response in 70-80% of patients and reducing JAK2 VAF by a mean 30-50% over 36 months ^[122]^A1a^[123]^A1a (1a). The PROUD-CONTI study demonstrated superiority over HU for molecular response ^[141]^D5.
Pegylated interferon alfa-2a 90-180 µg weekly is an alternative, though less well studied in PV ^[53]^C4.

Step 4: Second-Line Therapy

For patients intolerant or resistant to HU, ruxolitinib 10 mg twice daily is approved based on the RESPONSE trial (N=222), which showed 21% achieving hematocrit control and ≥35% spleen reduction at 32 weeks vs 1% with standard therapy (HR 0.58, 95% CI 0.42-0.79; NNT = 5) ^[113]^A1b. The MAJIC-PV trial confirmed ruxolitinib's superiority over best available therapy for complete response (43% vs 26%; OR 2.12, 90% CI 1.25-3.60) ^[112]^A1b. Rusfertide, a hepcidin mimetic, is emerging as a phlebotomy-sparing agent; the REVIVE trial showed 60% of patients achieved hematocrit control without phlebotomy vs 17% with placebo ^[115]^A1b.

Step 5: Monitoring and Transition

Monitor , hematocrit, and symptoms every 3-6 months. Assess for iron deficiency (ferritin <30 ng/mL) and supplement cautiously if symptomatic. Transition to cytoreduction if phlebotomy requirements exceed 6-8 per year or if symptoms worsen ^[49]^A1c.

Drug / Modality Comparison Table

Agent	Indication / Line	Starting Dose	Target / Max Dose	Key Monitoring	Evidence Level
Hydroxyurea	First-line cytoreduction	500 mg PO daily	1000-2000 mg daily	CBC, hematocrit, platelets	1b ^[1]^A1b^[49]^A1c
Ropeginterferon alfa-2b	First-line or second-line	250 µg SC q2wk	500 µg SC q2wk	CBC, LFTs, thyroid function, JAK2 VAF	1a ^[122]^A1a^[123]^A1a
Peginterferon alfa-2a	Alternative first-line	90 µg SC weekly	180 µg SC weekly	CBC, LFTs, thyroid function	4 ^[53]^C4
Ruxolitinib	Second-line (HU intolerant/resistant)	10 mg PO BID	25 mg PO BID	CBC, spleen size, symptoms	1b ^[112]^A1b^[113]^A1b
Rusfertide	Phlebotomy-sparing (investigational)	40 mg SC weekly	80 mg SC weekly	Hematocrit, phlebotomy frequency	1b ^[115]^A1b

What NOT to Do

Do not use phlebotomy alone in high-risk patients; cytoreduction is required ^[49]^A1c.
Do not administer aspirin if platelet count >1000 × 10⁹/L due to bleeding risk ^[111]^A1c.
Do not use hydroxyurea during pregnancy; switch to interferon ^[49]^A1c.
Do not target hematocrit <42% in women based on sex alone; the CYTO-PV trial used a uniform <45% threshold ^[2]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Target hematocrit in women	NCCN/ELN, <45% for all patients ^[49]^A1c^[111]^A1c	Some experts, <42% for women to account for lower normal range ^[67]^D5	Mild (no trial directly comparing sex-specific targets)	Most clinicians use <45% uniformly; individualize if symptoms persist.
First-line cytoreduction: HU vs interferon	NCCN, HU is first-line for most high-risk patients ^[49]^A1c	ELN, interferon may be preferred in younger patients or those desiring pregnancy ^[111]^A1c^[141]^D5	Moderate (different age-based recommendations)	HU remains standard; interferon is increasingly used in younger patients for potential disease modification.
Cytoreduction in low-risk patients	NCCN/ELN, not recommended unless symptomatic ^[49]^A1c^[111]^A1c	Real-world data, 22% of low-risk patients receive cytoreduction, with lower thrombosis rates ^[22]^B2b	Moderate (observational vs guideline)	Avoid routine cytoreduction in low-risk; consider only for severe symptoms or high phlebotomy burden.

Pearl: All patients should receive phlebotomy to maintain hematocrit <45% and low-dose aspirin unless contraindicated; cytoreduction is reserved for high-risk patients, with hydroxyurea as first-line and ropeginterferon or ruxolitinib as alternatives ^[49]^A1c^[111]^A1c^[2]^A1b.

Prognosis and Prognostic Factors

▸Median survival with modern therapy is 13-17 years for patients under 60; thrombosis remains the leading cause of death.
▸The PV Prognostic Score (age, leukocytosis, thrombosis history) stratifies 10-year survival from 85% (low-risk) to 45% (high-risk).
▸Additional mutations (ASXL1, SRSF2, IDH1/2) and high JAK2 V617F allele burden (>50%) independently predict transformation to myelofibrosis or AML.

HY High Yield: Remember that a JAK2 V617F allele burden >50% at diagnosis is an independent marker for progression to post-PV myelofibrosis (PPV-MF) and should prompt closer surveillance.

Once the diagnosis of Polycythemia Vera is established, the clinical course is largely determined by thrombotic risk and the potential for transformation to myelofibrosis (MF) or acute myeloid leukemia (AML). Without treatment, median survival is approximately 1.5 to 2 years from diagnosis; with modern , median survival extends to 13-17 years for patients aged <50 years, declining to about 5 years for those >80 years ^[59]^D5. The most frequent cause of death is thrombotic events (40-50%), followed by hematologic transformation (10-20%) and bleeding complications (5-10%).

Prognostic Stratification

The International Prognostic Score for PV (IPS-PV) and its updated molecular version (IPS-ET for ET is distinct; for PV the most validated tool is the PV Prognostic Score incorporating age >60 years, leukocytosis >15 × 10⁹/L, and history of thrombosis) categorizes patients into low-, intermediate-, and high-risk groups with 10-year survival rates of approximately 85%, 70%, and 45%, respectively ^[124]^D5. More recently, the MPN Genomic Classification by Grinfeld et al. integrates somatic mutations beyond JAK2 V617F to refine prediction. Patients with additional mutations in ASXL1, SRSF2, or IDH1/2 have significantly shorter overall and leukemia-free survival (HR 2.3, 95% CI 1.6-3.3) ^[64]^B3b^[59]^D5.

Key Prognostic Factors

Factor	Good Prognosis	Poor Prognosis
Age at diagnosis	<60 years	≥60 years ^[124]^D5
Leukocyte count	<15 × 10⁹/L	>15 × 10⁹/L ^[59]^D5
History of thrombosis	No	Yes (arterial or venous) ^[124]^D5
JAK2 V617F allele burden	<50%	>50% (higher risk of MF transformation) ^[64]^B3b
Additional mutations (ASXL1, SRSF2, IDH1/2)	Absent	Present ^[64]^B3b
Monocyte-to-lymphocyte ratio (MLR)	<0.28	>0.28 (predicts future thrombosis) ^[147]^B3b

Thrombosis Risk and Recurrence

The annual incidence of thrombotic events in PV is approximately 3-5% per year in patients treated to target (hematocrit <45%) ^[59]^D5. The landmark CYTO-PV study demonstrated that targeting a hematocrit <45% reduces the composite risk of cardiovascular death and major thrombosis from 5.0% to 1.1% per year (NNH not calculable; NNT estimated at 26 over 3 years) ^[124]^D5. Recurrent thrombosis occurs in 10-15% of high-risk patients despite adequate cytoreduction ^[112]^A1b. A rising monocyte-to-lymphocyte ratio (MLR >0.28) independently predicts thrombosis progression (OR 2.4, 95% CI 1.1-5.3) ^[147]^B3b.

Transformation to MF and AML

The cumulative risk of post-PV myelofibrosis (PPV-MF) is 15-20% at 10 years and 25-35% at 20 years ^[59]^D5. Transformation to AML occurs in approximately 5-10% at 10 years and 15-20% at 20 years; risk is higher in patients exposed to alkylating agents or radioactive phosphorus (now rarely used) ^[124]^D5. The presence of TP53 mutations or complex karyotype heralds rapid leukemic transformation (median survival <6 months post-AML) ^[64]^B3b.

Long-Term Sequelae and Functional Outcomes

Beyond survival, quality of life is substantially impaired: MPN-Symptom Assessment Form scores show that >70% of patients report moderate-to-severe fatigue, pruritus, or bone pain, even with controlled hematocrit ^[60]^B2b. Microvascular symptoms (headache, dizziness, visual disturbances) improve in 80-85% of patients with phlebotomy and cytoreduction ^[60]^B2b. Psychosocial burden, anxiety, depression, and fear of thrombosis, affects 25-40% of patients and correlates with lower treatment adherence ^[60]^B2b.

Pearl: In PV, a hematocrit target <45% halves the annual thrombosis rate, but the disease-modifying potential of peginterferon (particularly reducing JAK2 V617F allele burden) may further improve long-term outcomes, with molecular response rates >60% at 24 months ^[145]^B2b^[64]^B3b.

Special Populations

▸Pediatric PV requires interferon over hydroxyurea due to leukemogenic risk; pegylated interferon alfa-2a 90 mcg weekly is the preferred cytoreductive agent.
▸Pregnancy management centers on phlebotomy and low-dose aspirin; hydroxyurea is contraindicated, and interferon alfa is the cytoreductive option of choice.
▸Elderly patients need dose-adjusted cytoreduction (e.g., ruxolitinib 10 mg twice daily) and monitoring for comorbidities and drug interactions.

HY High Yield: Hydroxyurea is teratogenic; interferon alfa is the preferred cytoreductive agent during pregnancy.

of polycythemia vera requires tailored approaches in pediatric, pregnant, elderly, and immunocompromised patients, where standard protocols are modified to account for altered physiology, treatment toxicity, and competing risks.

Pediatrics

Childhood PV is rare; JAK2 V617F is present in approximately 30% of cases, a lower frequency than in adults ^[5]^B3b. Presentation may be familial, and diagnostic criteria follow the same WHO guidelines but with age-adjusted thresholds. Phlebotomy to maintain hematocrit <45% remains the cornerstone ^[2]^A1b. Cytoreduction with pegylated interferon alfa-2a (starting dose 90 mcg weekly) is preferred over hydroxyurea due to the latter's leukemogenic potential, particularly in younger patients with longer exposure horizons ^[19]^B3b^[53]^C4. Hydroxyurea is reserved for cases refractory to interferon.

Pregnancy

Pregnancy in PV carries heightened thrombotic risk for both mother and fetus. Hematocrit should be maintained <45% with phlebotomy. Low-dose (81 mg daily) is recommended for all patients unless contraindicated. Hydroxyurea is teratogenic and contraindicated; interferon alfa is the cytoreductive agent of choice when needed ^[53]^C4. Ruxolitinib should be avoided due to insufficient safety data. Delivery planning involves a multidisciplinary team including hematology and maternal-fetal medicine.

Elderly

Older patients have higher baseline thrombotic risk and more comorbidities, requiring careful dose adjustment. Hydroxyurea is first-line cytoreductive therapy, but renal function must guide dosing (e.g., reduce dose if creatinine clearance <60 mL/min). Ruxolitinib is effective for hydroxyurea-resistant or intolerant patients, but starting doses may be lowered (e.g., 10 mg twice daily instead of 20 mg) to minimize anemia and infection risk ^[113]^A1b^[154]^D5. Monitor for myelosuppression and drug interactions.

Immunocompromised

Patients on cytoreductive therapy, especially ruxolitinib, have increased infection risk, particularly and urinary tract infections ^[113]^A1b. Consider antiviral prophylaxis (e.g., ) during ruxolitinib therapy. Interferon alfa can exacerbate autoimmune conditions. Vaccinations (influenza, pneumococcal, herpes zoster) should be updated before initiating therapy.

Population	Key Modifications	Preferred Therapy	Monitoring
Pediatrics	Avoid hydroxyurea; use interferon	Pegylated interferon alfa-2a 90 mcg weekly	Growth, development, thyroid function
Pregnancy	Avoid hydroxyurea and ruxolitinib	Phlebotomy + low-dose aspirin; interferon if needed	Fetal ultrasound, thrombotic symptoms
Elderly	Dose-adjust cytoreductives for renal function	Hydroxyurea (renal-adjusted) or ruxolitinib 10 mg bid	Renal function, CBC, infections
Immunocompromised	Antiviral prophylaxis with ruxolitinib	Ruxolitinib with acyclovir prophylaxis	Herpes zoster, infections

Pearl: Special populations with PV require individualized management: interferon alfa is preferred in children and pregnant women, while elderly patients benefit from dose-adjusted cytoreduction and careful comorbidity monitoring; ruxolitinib use in immunocompromised patients mandates infection prophylaxis ^[53]^C4^[113]^A1b^[154]^D5.

References

[1]
Kiladjian JJ, Chevret S, Dosquet C et al.. “Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21911721 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, Special Populations
[2]
Marchioli R, Finazzi G, Specchia G et al.. “Cardiovascular events and intensity of treatment in polycythemia vera.” The New England journal of medicine (2012). PMID: 23216616 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, Special Populations
[3]
Pardanani A, Gotlib JR, Jamieson C et al.. “Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21220608 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations
[4]
Lee J, Axilbund J, Dalton WB et al.. “A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956534 ↗
L4CASE_REPORTCited in: Definition and Epidemiology, Clinical Presentation, Imaging, Management Overview, Special Populations
[5]
Teofili L, Giona F, Martini M et al.. “Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17369568 ↗
L3OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
[6]
Hultcrantz M, Kristinsson SY, Andersson TM et al.. “Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22802311 ↗
L2OTHERCited in: Definition and Epidemiology, Special Populations
[7]
Modi NB, Dinh P, Ajari I. “Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.” Clinical pharmacology in drug development (2025). PMID: 39888264 ↗
L1RCTCited in: Definition and Epidemiology
[8]
Batyrbekova N, Landtblom AR, Hultcrantz M et al.. “Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.” European journal of haematology (2026). PMID: 41717866 ↗
L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Special Populations
[9]
Bove FJ, Greek A, Gatiba R et al.. “Cancer Incidence among Marines and Navy Personnel and Civilian Workers Exposed to Industrial Solvents in Drinking Water at US Marine Corps Base Camp Lejeune: A Cohort Study.” Environmental health perspectives (2024). PMID: 39446420 ↗
L2COHORTCited in: Definition and Epidemiology
[10]
Barbui T, Scandura JM. “Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.” Blood advances (2026). PMID: 41370203 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[11]
Szuber N, Tefferi A, Gangat N. “JAK2 wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches.” Hematology. American Society of Hematology. Education Program (2025). PMID: 41347984 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
[12]
Szuber N, Guglielmelli P, Gangat N. “Topics of Interest in Women With Myeloproliferative Neoplasms.” American journal of hematology (2025). PMID: 40084464 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[13]
Barbui T, Stefano V, Rossi E et al.. “Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.” American journal of hematology (2025). PMID: 40062566 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[14]
Tefferi A, Gangat N, Loscocco GG et al.. “Essential Thrombocythemia: A Review.” JAMA (2025). PMID: 39869325 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[15]
Spivak JL. “Myeloproliferative Neoplasms: Challenging Dogma.” Journal of clinical medicine (2024). PMID: 39598101 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[16]
Tremblay D, Kremyanskaya M, Mascarenhas J et al.. “Diagnosis and Treatment of Polycythemia Vera: A Review.” JAMA (2025). PMID: 39556352 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[17]
Sankar K, Stein BL. “Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30545998 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
[18]
Khan MA, Naqvi SAA, Camoriano JK et al.. “Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study.” Cancer medicine (2025). PMID: 41317085 ↗
L2COHORTCited in: Risk Factors and Prevention, Clinical Presentation, Special Populations
[19]
Björkholm M, Derolf AR, Hultcrantz M et al.. “Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21537037 ↗
L3OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview, Special Populations
[20]
Barbui T, Carobbio A, De Stefano V et al.. “Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.” Annals of hematology (2023). PMID: 38060001 ↗
L1RCTCited in: Risk Factors and Prevention
[21]
Ngoc NT, Hau BB, Vuong NB et al.. “JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.” Molecular genetics & genomic medicine (2022). PMID: 35996819 ↗
L3SR_OBSCited in: Risk Factors and Prevention
[22]
Cohen I, Rozental A, Raanani P et al.. “Thrombosis in Low-Risk Polycythemia Vera: Insights From a Large Real-World Cohort.” Hematological oncology (2026). PMID: 42176275 ↗
L2OTHERCited in: Risk Factors and Prevention, Management Overview
[23]
Larsson AE, Renlund H, Andréasson B et al.. “Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population-Based Study on Treatment Patterns, Vascular Complications and Survival.” European journal of haematology (2026). PMID: 41531010 ↗
L2OTHERCited in: Risk Factors and Prevention
[24]
Guy A, Mansier O, Decilap M et al.. “Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.” Leukemia (2025). PMID: 41436639 ↗
L2OTHERCited in: Risk Factors and Prevention
[25]
Mishra R, Bagga A, Sharafeldin N et al.. “Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.” JCO oncology practice (2025). PMID: 41397215 ↗
L2OTHERCited in: Risk Factors and Prevention
[26]
Gangat N, Szuber N, Tefferi A. “JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management.” American journal of hematology (2025). PMID: 41123216 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation
[27]
Rivière E, Mansier O, Guy A et al.. “TRAKJAK: a complete blood count-based prediction of polycythemia vera at initial erythrocytosis workup to reduce financial and ecological costs.” The American journal of medicine (2025). PMID: 41109612 ↗
L3OTHERCited in: Risk Factors and Prevention
[28]
Duminuco A, Vaghela R, Virdee S et al.. “QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.” Leukemia (2025). PMID: 40707675 ↗
L3OTHERCited in: Risk Factors and Prevention
[29]
Ianotto JC, Curto-Garcia N, Lauermanova M et al.. “Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.” Haematologica (2019). PMID: 30679326 ↗
L5SR_OBSCited in: Histopathology and Molecular Biology
[30]
Spivak JL, Considine M, Williams DM et al.. “Two clinical phenotypes in polycythemia vera.” The New England journal of medicine (2014). PMID: 25162887 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Special Populations
[31]
Ortmann CA, Kent DG, Nangalia J et al.. “Effect of mutation order on myeloproliferative neoplasms.” The New England journal of medicine (2015). PMID: 25671252 ↗
L4OTHERCited in: Histopathology and Molecular Biology
[32]
Kirschner M, Bornemann A, Schubert C et al.. “Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms.” Annals of hematology (2019). PMID: 31748924 ↗
L4TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
[33]
Mullally A, Lane SW, Ball B et al.. “Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.” Cancer cell (2010). PMID: 20541703 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Management Overview
[34]
Radich J. “The molecular biology of myeloproliferative disorders.” Cancer cell (2010). PMID: 20609348 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[35]
Kiem D, Wagner S, Magnes T et al.. “The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.” International journal of molecular sciences (2021). PMID: 34502471 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[36]
Kjær L. “Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.” Cancers (2020). PMID: 32731609 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[37]
Bose P, Verstovsek S. “JAK2 inhibitors for myeloproliferative neoplasms: what is next?” Blood (2017). PMID: 28500170 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[38]
Saeidi K. “Myeloproliferative neoplasms: Current molecular biology and genetics.” Critical reviews in oncology/hematology (2015). PMID: 26697989 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[39]
Harrison CN, Garcia NC. “Management of MPN beyond JAK2.” Hematology. American Society of Hematology. Education Program (2014). PMID: 25696878 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[40]
Beer PA. “The pathogenesis of essential thrombocythemia.” Current opinion in hematology (2011). PMID: 21825979 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[41]
Scherber R, Mesa RA. “Future therapies for the myeloproliferative neoplasms.” Current hematologic malignancy reports (2011). PMID: 21080242 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[42]
Kvasnicka HM, Thiele J. “Prodromal myeloproliferative neoplasms: the 2008 WHO classification.” American journal of hematology (2010). PMID: 19844986 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[43]
Tefferi A, Skoda R, Vardiman JW. “Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.” Nature reviews. Clinical oncology (2009). PMID: 19806146 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[44]
Kandarpa M, Robinson D, Wu YM et al.. “Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38386293 ↗
L3OTHERCited in: Histopathology and Molecular Biology, Special Populations
[45]
Roug AS, Nyvold CG, Juhl-Christensen C et al.. “A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.” European journal of haematology (2011). PMID: 21689158 ↗
L4CASE_REPORTCited in: Histopathology and Molecular Biology
[46]
Pescia C, Lopez G, Cattaneo D et al.. “The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.” Leukemia research (2023). PMID: 38016412 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[47]
Putter JS, Seghatchian J. “Polycythaemia vera: molecular genetics, diagnostics and therapeutics.” Vox sanguinis (2021). PMID: 33634867 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[48]
Pavithran K, Pande SB. “Janus kinase inhibitors: jackpot or potluck?” Oncology reviews (2012). PMID: 25992203 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[49]
Gerds AT, Gotlib J, Ali H et al.. “Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36075392 ↗
L1GUIDELINECited in: Clinical Presentation, Management Overview
[50]
Mesa RA, Jamieson C, Bhatia R et al.. “NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28982745 ↗
L1GUIDELINECited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors
[51]
Mesa R, Jamieson C, Bhatia R et al.. “Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956542 ↗
L1GUIDELINECited in: Clinical Presentation, Management Overview
[52]
Stein BL, Gotlib J, Arcasoy M et al.. “Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25870379 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
[53]
Quintás-Cardama A, Kantarjian H, Manshouri T et al.. “Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19826111 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
[54]
Pardanani A, Harrison C, Cortes JE et al.. “Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.” JAMA oncology (2015). PMID: 26181658 ↗
L1RCTCited in: Clinical Presentation, Imaging, Management Overview, Prognosis and Prognostic Factors
[55]
Gangaraju R, Kim SJ, Dong JF et al.. “Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28596255 ↗
L4CASE_REPORTCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors
[56]
Tefferi A, Vainchenker W. “Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21220604 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
[57]
Kander EM, Moliterno AR, Rademaker A et al.. “Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27697978 ↗
L4OTHERCited in: Clinical Presentation, Management Overview, Special Populations
[58]
McFarland DC, Shaffer KM, Polizzi H et al.. “Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 29223988 ↗
L4OTHERCited in: Clinical Presentation
[59]
Tefferi A, Pardanani A. “Myeloproliferative Neoplasms: A Contemporary Review.” JAMA oncology (2015). PMID: 26182311 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
[60]
Geyer H, Scherber R, Kosiorek H et al.. “Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26598745 ↗
L2OTHERCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
[61]
Tam CS, Kantarjian H, Cortes J et al.. “Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19786661 ↗
L3OTHERCited in: Clinical Presentation, Management Overview, Special Populations
[62]
Neumark N, Jalowiec KA, Tichelli A et al.. “Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study.” Annals of hematology (2026). PMID: 41661348 ↗
L3COHORTCited in: Clinical Presentation
[63]
Cai Y, Wang Y, Zhang P et al.. “Gender influences prognosis of classical BCR::ABL1 negative myeloproliferative neoplasms: a retrospective cohort study.” Discover oncology (2025). PMID: 41413374 ↗
L3COHORTCited in: Clinical Presentation
[64]
Grinfeld J, Nangalia J, Baxter EJ et al.. “Classification and Personalized Prognosis in Myeloproliferative Neoplasms.” The New England journal of medicine (2018). PMID: 30304655 ↗
L3OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors
[65]
Scott LM, Tong W, Levine RL et al.. “JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.” The New England journal of medicine (2007). PMID: 17267906 ↗
L3OTHERCited in: Clinical Presentation
[66]
Nangalia J, Massie CE, Baxter EJ et al.. “Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.” The New England journal of medicine (2013). PMID: 24325359 ↗
L3OTHERCited in: Clinical Presentation
[67]
Ellis MH, Barbui T, Tefferi A. “Polycythemia vera.” Mayo Clinic proceedings (2026). PMID: 41902804 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
[68]
Ma X, Zhou Z, Gu S et al.. “Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs).” Cancers (2025). PMID: 41097669 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[69]
Loscocco GG, Gangat N, Guglielmelli P et al.. “Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models.” Expert review of molecular diagnostics (2025). PMID: 41074259 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
[70]
Bruno R, Bolletta E, Gozzi F et al.. “Anterior Segment Involvement in Polycythemia Vera: A Case Report and Review of Literature.” Ocular immunology and inflammation (2025). PMID: 41114646 ↗
L4CASE_REPORTCited in: Clinical Presentation
[71]
Sharda AV, Bogue T, Barr A et al.. “Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34400417 ↗
L2OTHERCited in: Clinical Presentation, Special Populations
[72]
Wilkins BS, Erber WN, Bareford D et al.. “Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.” Blood (2007). PMID: 17885079 ↗
L4RCTCited in: Biopsy and Histologic Diagnosis
[73]
Bousquet M, Le Guellec S, Quelen C et al.. “Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.” Human pathology (2006). PMID: 16949922 ↗
L4COHORTCited in: Biopsy and Histologic Diagnosis
[74]
Thiele J, Kvasnicka HM. “Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.” Pathobiology : journal of immunopathology, molecular and cellular biology (2007). PMID: 17587880 ↗
L1REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
[75]
Kvasnicka HM, Thiele J. “Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.” Pathobiology : journal of immunopathology, molecular and cellular biology (2007). PMID: 17587877 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
[76]
Hägglund H, Yavuz AS, Dreimane A et al.. “Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle.” European journal of haematology (2020). PMID: 33010068 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
[77]
Chen L, Xiao H, Hu Z. “Cerebral Hemorrhage of a 50-Year-Old Female Patient with Polycythemia Vera.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2019). PMID: 31126786 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
[78]
Putra J, Toor A, Noce TA et al.. “Multiple liver lesions in a patient with Budd-Chiari syndrome secondary to polycythemia vera.” Annals of hepatology (2015). PMID: 26019042 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
[79]
Vytrva N, Stacher E, Regitnig P et al.. “Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.” Archives of pathology & laboratory medicine (2014). PMID: 25171702 ↗
L3CASE_REPORTCited in: Biopsy and Histologic Diagnosis
[80]
Mattei TA, Higgins M, Joseph F et al.. “Ectopic extramedullary hematopoiesis: evaluation and treatment of a rare and benign paraspinal/epidural tumor.” Journal of neurosurgery. Spine (2013). PMID: 23330877 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
[81]
Mirza I, Frantz C, Clarke G et al.. “Transformation of polycythemia vera to chronic myelogenous leukemia.” Archives of pathology & laboratory medicine (2007). PMID: 17979493 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
[82]
Slot S, van de Donk NWCJ, Otten RHJ et al.. “The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.” Cancer imaging : the official publication of the International Cancer Imaging Society (2021). PMID: 33879266 ↗
L1SR_OBSCited in: Imaging
[83]
Chiu YC, Chang WC, Chiu YC. “Early catheter-directed portal vein thrombolysis in myeloproliferative disorder-related diffuse mesenteric venous ischemia: A case report.” World journal of gastroenterology (2026). PMID: 41640868 ↗
L4CASE_REPORTCited in: Imaging, Management Overview, Special Populations
[84]
Trifan G, Shafi N, Testai FD. “Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2018). PMID: 30056970 ↗
L5CASE_REPORTCited in: Imaging
[85]
Crespo AM, Abraira L, Guanyabens N et al.. “Recurrent Stroke with Rapid Development of Intracranial Stenoses in Polycythemia Vera.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2016). PMID: 26825349 ↗
L4CASE_REPORTCited in: Imaging
[86]
Lee J, Lim YM, Kim KK. “A case of spinal cord infarction caused by polycythemia vera.” Spinal cord (2015). PMID: 25900285 ↗
L4CASE_REPORTCited in: Imaging
[87]
Huang HC, Wu YC, Shih LY et al.. “Reversible abnormal functional neuroimaging presentations in polycythemia vera with chorea.” Journal of neurology (2011). PMID: 21559940 ↗
L4CASE_REPORTCited in: Imaging
[88]
Stanzani Maserati M. “Migraine attacks, aura, and polycythemia: a vasculoneural pathogenesis?” Journal of neural transmission (Vienna, Austria : 1996) (2010). PMID: 21161709 ↗
L4CASE_REPORTCited in: Imaging
[89]
Sørensen AL, Bjørn ME, Riley CH et al.. “B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.” European journal of haematology (2019). PMID: 31297883 ↗
L1TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
[90]
Taniguchi Y, Tanaka H, Luis EJ et al.. “Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.” International journal of hematology (2017). PMID: 28780601 ↗
L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
[91]
Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. “Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.” BMC cancer (2019). PMID: 31208359 ↗
L1SR_OBSCited in: Molecular Diagnostics and Biomarkers
[92]
Marin Oyarzún CP, Carestia A, Lev PR et al.. “Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms.” Scientific reports (2016). PMID: 27958278 ↗
L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
[93]
Schmidt AE, Oh ST. “Pathology consultation on myeloproliferative neoplasms.” American journal of clinical pathology (2012). PMID: 22706852 ↗
L5CASE_REPORTCited in: Molecular Diagnostics and Biomarkers
[94]
Mansier O, Lippert E, Benajiba L et al.. “A molecular signature predicts hematologic evolution in polycythemia vera patients.” Leukemia (2025). PMID: 40533498 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[95]
Handa S, Schaniel C, Tripodi J et al.. “HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis.” Leukemia (2024). PMID: 39715853 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[96]
Walter W, Nadarajah N, Hutter S et al.. “Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.” Leukemia (2024). PMID: 39341969 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[97]
Tripodi J, Hoffman R, Tremblay D et al.. “Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression.” International journal of molecular sciences (2024). PMID: 38612873 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers
[98]
Chin-Yee B, Matyashin M, Cheong I et al.. “Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review.” CMAJ open (2022). PMID: 36347562 ↗
L2REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[99]
Yung Y, Lee E, Chu HT et al.. “Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.” International journal of molecular sciences (2021). PMID: 33440869 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[100]
Leal AD, Thompson CA, Wang AH et al.. “Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2015). PMID: 26564251 ↗
L2RCTCited in: Staging
[101]
Santos FP, Kantarjian HM, Jain N et al.. “Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.” Blood (2009). PMID: 20008298 ↗
L4TRIAL_NONRANDOMCited in: Staging
[102]
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V et al.. “Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.” Blood (2015). PMID: 26261238 ↗
L4TRIAL_NONRANDOMCited in: Staging
[103]
Rampal R, Mascarenhas J. “Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.” Current opinion in hematology (2014). PMID: 24366192 ↗
L5REVIEW_NARRATIVECited in: Staging
[104]
Tallarico M, Odenike O. “Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.” Current hematologic malignancy reports (2015). PMID: 25893311 ↗
L5REVIEW_NARRATIVECited in: Staging
[105]
Tibes R, Mesa RA. “Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?” Leukemia & lymphoma (2011). PMID: 21599574 ↗
L5REVIEW_NARRATIVECited in: Staging
[106]
Deadmond MA, Smith-Gagen JA. “Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.” Journal of cancer research and clinical oncology (2015). PMID: 25968903 ↗
L2OTHERCited in: Staging
[107]
Prakash S, Hoffman R, Barouk S et al.. “Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.” Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (2012). PMID: 22388763 ↗
L4OTHERCited in: Staging
[108]
Ruan GR, Jiang B, Li LD et al.. “MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.” Hematological oncology (2010). PMID: 19274616 ↗
L4OTHERCited in: Staging
[109]
Krahling T, Balassa K, Kiss KP et al.. “Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2015). PMID: 26487696 ↗
L3OTHERCited in: Staging
[110]
Gowin K, Thapaliya P, Samuelson J et al.. “Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.” Haematologica (2012). PMID: 22419578 ↗
L4OTHERCited in: Staging
[111]
Barbui T, Barosi G, Birgegard G et al.. “Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21205761 ↗
L1GUIDELINECited in: Management Overview
[112]
Harrison CN, Nangalia J, Boucher R et al.. “Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37126762 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors
[113]
Vannucchi AM, Kiladjian JJ, Griesshammer M et al.. “Ruxolitinib versus standard therapy for the treatment of polycythemia vera.” The New England journal of medicine (2015). PMID: 25629741 ↗
L1RCTCited in: Management Overview, Special Populations
[114]
Harrison C, Kiladjian JJ, Al-Ali HK et al.. “JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.” The New England journal of medicine (2012). PMID: 22375970 ↗
L1RCTCited in: Management Overview, Special Populations
[115]
Kremyanskaya M, Kuykendall AT, Pemmaraju N et al.. “Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.” The New England journal of medicine (2024). PMID: 38381675 ↗
L1RCTCited in: Management Overview
[116]
Verstovsek S, Kantarjian H, Mesa RA et al.. “Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.” The New England journal of medicine (2010). PMID: 20843246 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
[117]
How J, Hobbs G. “Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia Vera.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36075385 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[118]
How J, Hobbs GS. “A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32886896 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
[119]
McFarland DC, Polizzi H, Mascarenhas J et al.. “Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956541 ↗
L4OTHERCited in: Management Overview, Special Populations
[120]
Bose P, Verstovsek S. “Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956543 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[121]
Mesa RA. “NCCN Debuts New Guidelines for Myeloproliferative Neoplasms.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28515254 ↗
L5OTHERCited in: Management Overview
[122]
Elgadi A, Wagealla M, Noorallah T et al.. “Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis.” Annals of hematology (2026). PMID: 42068356 ↗
L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
[123]
Nada EA, Elfagieh MA, Abdelsalam F et al.. “Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.” Annals of hematology (2025). PMID: 41238945 ↗
L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
[124]
Stein BL, Oh ST, Berenzon D et al.. “Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26324368 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
[125]
Fleischman A, Li J, Tabban A et al.. “Telehealth-Delivered Dietary Counseling in Myeloproliferative Neoplasms: A Randomized Feasibility Study.” Nutrients (2026). PMID: 41978208 ↗
L1RCTCited in: Management Overview, Special Populations
[126]
Yumin Z, Yuliang Z, Guozi W et al.. “Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription in the treatment of polycythemia vera with heat toxin and blood stasis syndrome.” Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2025). PMID: 41376227 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[127]
El Bouchtaoui M, Do Cruzeiro M, Leboeuf C et al.. “A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31004003 ↗
L4CASE_REPORTCited in: Management Overview
[128]
Inano T, Sugimoto Y, Ohishi K et al.. “Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study.” International journal of hematology (2026). PMID: 41801560 ↗
L2TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[129]
Wernig G, Kharas MG, Okabe R et al.. “Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.” Cancer cell (2008). PMID: 18394554 ↗
L5OTHERCited in: Management Overview, Prognosis and Prognostic Factors
[130]
Walden P, Hummel N, Kopiec A et al.. “Evaluating the feasibility of a network meta-analysis comparing treatment options in polycythemia vera.” Journal of comparative effectiveness research (2025). PMID: 41328632 ↗
L5SR_OBSCited in: Management Overview
[131]
Lee HJ, Daver N, Kantarjian HM et al.. “The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23209034 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[132]
Gurska LM, Okabe R, Schurer A et al.. “Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36537918 ↗
L5OTHERCited in: Management Overview
[133]
Patel AB, Vellore NA, Deininger MW. “New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26933174 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[134]
Mascarenhas J, Hoffman R. “Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22474318 ↗
L5OTHERCited in: Management Overview
[135]
Liu PC, Caulder E, Li J et al.. “Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19887489 ↗
L5OTHERCited in: Management Overview
[136]
Mayo R, Bishop MW, Crawford B. “Polycythemia vera as a cause of systemic hypertension.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 41670655 ↗
L4CASE_REPORTCited in: Management Overview
[137]
Bartalucci N, Tarantino D, Loscocco GG et al.. “A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.” American journal of hematology (2025). PMID: 41335026 ↗
L4CASE_REPORTCited in: Management Overview
[138]
Liu W, Ren Y, Liang Y et al.. “Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.” Hematology (Amsterdam, Netherlands) (2026). PMID: 42237068 ↗
L3COHORTCited in: Management Overview
[139]
Chang YS, Liu CY, Chen YW et al.. “Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study.” Clinical lymphoma, myeloma & leukemia (2025). PMID: 40683770 ↗
L2COHORTCited in: Management Overview
[140]
Wu C, Wang Y, Zhang Q et al.. “BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms.” Frontiers in immunology (2026). PMID: 42311686 ↗
L5OTHERCited in: Management Overview
[141]
Silver RT, Hasselbalch HC. “A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.” Leukemia (2026). PMID: 41951941 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[142]
Roca Mora MM, Afzal F, Guimaraes CR et al.. “Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta-analysis.” APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (2024). PMID: 39377511 ↗
L1SR_OBSCited in: Prognosis and Prognostic Factors
[143]
Mascarenhas J, Mascarenhas J, Bose P et al.. “ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.” Acta haematologica (2025). PMID: 40043697 ↗
L1RCTCited in: Prognosis and Prognostic Factors
[144]
Heidel FH, De Stefano V, Zaiss M et al.. “Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM).” Leukemia (2025). PMID: 40281326 ↗
L1TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
[145]
Yoon SY, Yoon SS, Yang DH et al.. “Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.” International journal of cancer (2025). PMID: 40087986 ↗
L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
[146]
Sørensen AL, Skov V, Kjær L et al.. “Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.” Blood advances (2024). PMID: 39163611 ↗
L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
[147]
Abdelfattah A, Issa GS, Al-Arareh H et al.. “Monocyte-To-Lymphocyte Ratio as a Predictor of Thrombosis Progression in Patients With Polycythemia Vera: A Retrospective Study.” International journal of laboratory hematology (2025). PMID: 41213725 ↗
L3COHORTCited in: Prognosis and Prognostic Factors, Special Populations
[148]
Yacoub A, Abu-Zeinah G, Qin A et al.. “PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.” Annals of hematology (2025). PMID: 39804351 ↗
L5TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
[149]
Kirito K, Sugimoto Y, Gotoh A et al.. “Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.” International journal of hematology (2024). PMID: 39361233 ↗
L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
[150]
Tønne Nesse AS, Gjelberg HK, Sandnes M et al.. “Non-MPL-W515K/L mutations in myeloproliferative neoplasms: Insights from two case reports and a review of the literature.” Expert review of hematology (2025). PMID: 40579775 ↗
L4SR_OBSCited in: Special Populations
[151]
Emanuel RM, Dueck AC, Geyer HL et al.. “Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23071245 ↗
L2OTHERCited in: Special Populations
[152]
Geron I, Abrahamsson AE, Barroga CF et al.. “Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.” Cancer cell (2008). PMID: 18394555 ↗
L2OTHERCited in: Special Populations
[153]
Kalota A, Jeschke GR, Carroll M et al.. “Intrinsic resistance to JAK2 inhibition in myelofibrosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 23386690 ↗
L4OTHERCited in: Special Populations
[154]
De Fazio L, Molica M, Simio C et al.. “Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.” Leukemia & lymphoma (2026). PMID: 41982071 ↗
L5REVIEW_NARRATIVECited in: Special Populations